Advertisement

Breast Cancer

Joint Analysis Confirms Benefit of Anthracyclines for High-Risk Early-Stage Breast Cancer

For the treatment of high-risk, HER2-negative early-stage breast cancer, anthracyclines were confirmed as beneficial in a joint analysis of the Anthracyclines in Early Breast Cancer (ABC) trials. Presented at the 2016 ASCO Annual Meeting, the joint analysis of the ABC trials validated taxane plus anthracycline as the preferred regimen for high-risk patients.1

 

Solid Tumors

‘Liquid Biopsy’ Stacks Up Well to Tissue Biopsy in Detecting Tumor-Specific Mutations

So-called liquid biopsy identified cancer mutations in 85% of all advanced tumors, in the largest-ever evaluation of circulating tumor DNA (ctDNA) in the blood.1

 

Gynecologic Cancers

In the Neoadjuvant Era, Intraperitoneal Chemotherapy Is of Benefit in Advanced Ovarian Cancer

The role of intraperitoneal (IP) chemotherapy in the treatment of advanced ovarian cancer has been debated for a long time. According to a new study presented at the 2016 ASCO Annual Meeting, a combination of IP and intravenous (IV) chemotherapy appears more effective than IV chemotherapy alone in women with optimally resected advanced ovarian cancer following neoadjuvant chemotherapy, reducing the progressive disease rate at 9 months by 18.9%.1

 


Advertisement

More Top Stories

Lung Cancer

Vali A. Papadimitrakopoulou, MD, and Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App

Extending ASCO’s Influence Globally to Improve Patient Care

On June 27, 2016, Clifford A. Hudis, MD, FACP, FASCO, will begin his tenure as Chief Executive Officer of ASCO, succeeding Allen S. Lichter, MD, FASCO, who presided over the Society and the Conquer Cancer Foundation of ASCO since 2006. Dr. Hudis’ dedication to ASCO dates back more than 25 years ...

Advertisement

CAR T-Cell Therapy Using Double Target Aimed at Solid Tumors in Preclinical Models

Chimeric antigen receptors (CARs), engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells.

Now, in a report published...

Lung Cancer

Vali A. Papadimitrakopoulou, MD, and Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App

ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships

ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined ­CancerLinQ™, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. ­CancerLinQ is already up and running in a number of practices and drawing on approximately...

Lung Cancer Alliance Supports Two Young Investigator Awards

The Conquer Cancer Foundation of ASCO (CCF) has received generous support from Lung Cancer Alliance to fund a 2016 and 2017 Young Investigator Award (YIA) in lung cancer. Lung Cancer Alliance has a more than 20-year history of working to save lives and advance research by empowering those living...

Influence of Age and Comorbidities on Rates of Colorectal Cancer Screening in the Elderly

Colorectal cancer (CRC) is a common and costly disease, largely of the elderly, with nearly 25% of cases diagnosed among patients aged 75–84 years. However, but the guidelines for CRC screening of Americans aged 75 or older vary according to the source. In a study published by Klabunde et al...

Breast Cancer

Nikhil Wagle, MD, on The Metastatic Breast Cancer Project: Progress Report

Breast Cancer

Prolonged Progression-Free Survival With Addition of Palbociclib to Fulvestrant in HER2-Negative Metastatic Breast Cancer

As reported in The Lancet Oncology by Massimo Cristofanilli, MD, of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, and colleagues, the final results of the phase III PALOMA-3 trial showed that the addition of the CDK4/CDK6 inhibitor palbociclib (Ibrance) to...

Advertisement

USPSTF Issues New Recommendations for Colorectal Cancer Screening

As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has issued new recommendations for colorectal cancer screening. In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF...